Risk factors for immune-related adverse events: what have we learned and what lies ahead?

Immune checkpoint inhibitors (ICIs) have heralded the advent of a new era in oncology by holding the promise of prolonged survival in severe and otherwise treatment-refractory advanced cancers. However, the remarkable antitumor efficacy of these agents is overshadowed by their potential for inducing...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiaoyan, Shi, Yuequan, Zhang, Dongming, Zhou, Qing, Liu, Jia, Chen, Minjiang, Xu, Yan, Zhao, Jing, Zhong, Wei, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565046/
https://www.ncbi.nlm.nih.gov/pubmed/34732257
http://dx.doi.org/10.1186/s40364-021-00314-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8565046/
https://www.ncbi.nlm.nih.gov/pubmed/34732257
http://dx.doi.org/10.1186/s40364-021-00314-8

Ejemplares similares